Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...

NEW YORK (Reuters) — The chief executive of Germany’s BioNTech SE said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States ...

BERLIN, Oct 30 (Reuters) - BioNTech (22UAy.F), opens new tab, Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

Strategic collaborations with partners such as Bristol-Myers Squibb and Genentech are intended to accelerate progress. While the pipeline is broadening, management notes that none of the oncology ...

The independent journey of CureVac on public markets has concluded. The Nasdaq exchange has suspended trading of the ...

BERLIN (AP) - Europe can achieve herd immunity against the coronavirus within the next four months, the head of German pharmaceutical company BioNTech, which developed the first widely approved ...

BERLIN, Jan 1 (Reuters) - BioNTech (22UAy.DE), opens new tab is working flat out with partner Pfizer (PFE.N), opens new tab to boost production of their COVID-19 vaccine, its founders said, warning ...

MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of ...